Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α
- 1 June 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (11), 3849-3854
- https://doi.org/10.1158/0008-5472.can-04-0322
Abstract
Lipid-lowering fibrate drugs function as agonists for the nuclear receptor peroxisome proliferator-activated receptor α (PPARα). Sustained activation of PPARα leads to the development of liver tumors in rats and mice. However, humans appear to be resistant to the induction of peroxisome proliferation and the development of liver cancer by fibrate drugs. The molecular basis of this species difference is not known. To examine the mechanism determining species differences in peroxisome proliferator response between mice and humans, a PPARα-humanized mouse line was generated in which the human PPARα was expressed in liver under control of the tetracycline responsive regulatory system. The PPARα-humanized and wild-type mice responded to treatment with the potent PPARα ligand Wy-14643 as revealed by induction of genes encoding peroxisomal and mitochondrial fatty acid metabolizing enzymes and resultant decrease of serum triglycerides. However, surprisingly, only the wild-type mice and not the PPARα-humanized mice exhibited hepatocellular proliferation as revealed by elevation of cell cycle control genes, increased incorporation of 5-bromo-2′-deoxyuridine into hepatocyte nuclei, and hepatomegaly. These studies establish that following ligand activation, the PPARα-mediated pathways controlling lipid metabolism are independent from those controlling the cell proliferation pathways. These findings also suggest that structural differences between human and mouse PPARα are responsible for the differential susceptibility to the development of hepatocarcinomas observed after treatment with fibrates. The PPARα-humanized mice should serve as models for use in drug development and human risk assessment and to determine the mechanism of hepatocarcinogenesis of peroxisome proliferators.Keywords
This publication has 31 references indexed in Scilit:
- Large Dimeric Ligands with Favorable Pharmacokinetic Properties and Peroxisome Proliferator-Activated Receptor Agonist Activity in Vitro and in VivoJournal of Medicinal Chemistry, 2003
- Human Peroxisome Proliferator-activated Receptor α (PPARα) Supports the Induction of Peroxisome Proliferation in PPARα-deficient Mouse LiverPublished by Elsevier BV ,2001
- Identification of a subtype selective human PPARα agonist through parallel-array synthesisBioorganic & Medicinal Chemistry Letters, 2001
- Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)Published by Elsevier BV ,1998
- Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Effect on the expression of c-met, c-myc and PPAR-α in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14, 643Carcinogenesis: Integrative Cancer Research, 1996
- CDK1 is a marker of proliferation in human lymphoid cellsInternational Journal of Cancer, 1995
- The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐upJournal of Internal Medicine, 1994
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987